GlassScriptPhysician profile
Ariana Herbert
NPI 1013337526
$5,041.63
in general payments reported to CMS, 2019-2025
30 companies · $856 in 2025
The $856 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $270 · 2021: $650 · 2022: $960 · 2023: $707 · 2024: $1,097 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,832.01 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $822.37 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $776.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $179.13 | 2025 | Caplyta |
| Amarin Pharma, INC. | $134.80 | 2019-2021 | |
| Polarityte, INC. | $124.40 | 2020 | |
| Acerus Pharmaceuticals Corporation | $122.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.42 | 2019-2022 | |
| Dynavax Technologies Corporation | $93.65 | 2019 | |
| Merck Sharp & Dohme LLC | $92.60 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Corium, LLC | $89.34 | 2022-2024 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $88.27 | 2019-2025 | Farxiga, Breztri |
| Astellas Pharma US INC | $53.91 | 2024-2025 | Veozah |
| Lilly USA, LLC | $52.33 | 2022-2025 | Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $52.23 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $50.41 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.39 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $44.08 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $39.48 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.42 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.43 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $30.70 | 2021 | |
| Aimmune Therapeutics, INC. | $27.91 | 2024-2025 | Zenpep |
| Allergan, INC. | $23.66 | 2020 | |
| Eisai INC. | $18.48 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.25 | 2023 | Qelbree |
| Pfizer INC. | $16.12 | 2020 | |
| Almatica Pharma LLC | $12.52 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.16 | 2019 | |
| Dexcom, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariana Herbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.